The partnership between Ginkgo Bioworks and Prozomix focuses on developing sustainable enzymes for API manufacturing, a move that aligns with the growing demand for sustainable production methods in the pharmaceutical industry. This collaboration could lead to the development of innovative products, enhancing Ginkgo Bioworks' product portfolio and potentially opening up new revenue streams. The positive impact on Ginkgo Bioworks' stock price in the short term is likely due to investor optimism about the company's involvement in sustainable and innovative manufacturing solutions.